Related references
Note: Only part of the references are listed.New HCV therapies on the horizon
J. Vermehren et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Promising Targets for Anti-Hepatitis C Virus Agents
T. Yoshida et al.
CURRENT MEDICINAL CHEMISTRY (2011)
TELAPREVIR-BASED REGIMENS SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL
Ira M. Jacobson et al.
GASTROENTEROLOGY (2011)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN INCREASED SUSTAINED VIROLOGIC RESPONSE RATES IN TREATMENT-NAIVE PATIENTS REGARDLESS OF RACE OR ETHNICITY
G. M. Dusheiko et al.
JOURNAL OF HEPATOLOGY (2011)
Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus
K. Morikawa et al.
JOURNAL OF VIRAL HEPATITIS (2011)
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients
David R. Nelson
LIVER INTERNATIONAL (2011)
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Current Therapies for Chronic Hepatitis C
McKenzie C. Ferguson
PHARMACOTHERAPY (2011)
Mixing the right hepatitis C inhibitor cocktail
Michael A. Gelman et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or-2b to Patients With Chronic Hepatitis C
Patrick Marcellin et al.
GASTROENTEROLOGY (2011)
Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression
Gary L. Davis et al.
GASTROENTEROLOGY (2010)
Sustained Virologic Response Prevents the Development of Esophageal Varices in Compensated, Child-Pugh Class A Hepatitis C Virus-Induced Cirrhosis. A 12-Year Prospective Follow-up Study
Savino Bruno et al.
HEPATOLOGY (2010)
Institute of Medicine Recommendations for The Prevention and Control of Hepatitis B and C
Abigail E. Mitchell et al.
HEPATOLOGY (2010)
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
Tara L. Kieffer et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Telaprevir for Previously Treated Chronic HCV Infection.
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care
Leen Delang et al.
VIRUSES-BASEL (2010)
A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
Bambang S. Adiwijaya et al.
PLOS COMPUTATIONAL BIOLOGY (2010)
Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials
Aarthi Chary et al.
REVIEWS ON RECENT CLINICAL TRIALS (2010)
Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b A Randomized Trial
Donald M. Jensen et al.
ANNALS OF INTERNAL MEDICINE (2009)
Telaprevir: Hope on the Horizon, Getting Closer
Ilan S. Weisberg et al.
CLINICS IN LIVER DISEASE (2009)
Telaprevir: A Promising Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
I. Gentile et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Serine protease inhibitors as anti-hepatitis C virus agents
Markus Reiser et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2009)
Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
Thierry Poynard et al.
GASTROENTEROLOGY (2009)
Diagnosis, Management, and Treatment of Hepatitis C: An Update
Marc G. Ghany et al.
HEPATOLOGY (2009)
Retreating Chronic Hepatitis C with Daily Interferon Alfacon-1/Ribavirin After Nonresponse to Pegylated Interferon/Ribavirin: DIRECT Results
Bruce R. Bacon et al.
HEPATOLOGY (2009)
Public Health Impact of Antiviral Therapy for Hepatitis C in the United States
Michael L. Volk et al.
HEPATOLOGY (2009)
A Step Forward in Therapy for Hepatitis C
Jay H. Hoofnagle
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Christophe Hezode et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
Eric Lawitz et al.
JOURNAL OF HEPATOLOGY (2008)
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects
Doug J. Bartels et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Phenotypic characterization of resistant Val(36) variants of hepatitis C virus NS3-4A serine protease
Yi Zhou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Hepatitis C: a clinical review
A. A. Modi et al.
ORAL DISEASES (2008)
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
Bart J. Veldt et al.
ANNALS OF INTERNAL MEDICINE (2007)
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse
Thomas Vanwolleghem et al.
GASTROENTEROLOGY (2007)
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
Tara L. Kieffer et al.
HEPATOLOGY (2007)
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
Nicole Forestier et al.
HEPATOLOGY (2007)
Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants -: Sensitivity to telaprevir (VX-950) and interferon α
Yi Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics
Robert B. Perni et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Epidemiology of hepatitis C virus infection
Miriam J. Alter
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: A phase Ib, placebo-controlled, randomized study
Hendrik W. Reesink et al.
GASTROENTEROLOGY (2006)
VX-950, a novel hepatitis C virus (HCV) NS34A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells
K Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
RB Perni et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Therapy of hepatitis C: From empiricism to eradication
JM Pawlotsky
HEPATOLOGY (2006)
Treating viral hepatitis C: Efficacy, side effects, and complications
M. P. Manns et al.
GUT (2006)
In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061
C Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Unravelling hepatitis C virus replication from genome to function
BD Lindenbach et al.
NATURE (2005)
How does ribavirin improve interferon-α response rates in hepatitis C virus infection?
JM Pawlotsky
JOURNAL OF HEPATOLOGY (2005)
Discovery of small-molecule inhibitors of HCVNS3-4A protease as potential therapeutic agents against HCV infection
SH Chen et al.
CURRENT MEDICINAL CHEMISTRY (2005)
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 - Structural analysis indicates different resistance mechanisms
C Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Inhibitors of hepatitis C virus NS3•4A protease.: Part 3:: P2 proline variants
RB Perni et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Inhibitors of hepatitis C virus NS3•4A protease 2.: Warhead SAR and optimization
RB Perni et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor
Y Yip et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
A long-term latent reservoir for HIV-1: discovery and clinical implications
JD Siliciano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA, replication and facilitates viral RNA clearance in replicon cells
K Lin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients
H Hinrichsen et al.
GASTROENTEROLOGY (2004)
Natural history of decompensated hepatitis C virus-related cirrhosis.: A study of 200 patients
R Planas et al.
JOURNAL OF HEPATOLOGY (2004)
Inhibitors of hepatitis C virus NS3•4A protease 1.: Non-charged tetrapeptide variants
RB Perni et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
D Lamarre et al.
NATURE (2003)
Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection
YS Tsantrizos et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2003)
Hepatitis C virus replicons: potential role for drug development
R Bartenschlager
NATURE REVIEWS DRUG DISCOVERY (2002)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Amorphous pharmaceutical solids: preparation, characterization and stabilization
L Yu
ADVANCED DRUG DELIVERY REVIEWS (2001)
Prediction of drug absorption using multivariate statistics
WJ Egan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
